Soleno Therapeutics Inc (SLNO) Institutional Ownership

Ownership Summary

A total of 238 institutions have reported a stake in Soleno Therapeutics Inc (NASDAQ:SLNO) as of September 2025, according to recent 13F filings with the SEC.

• Institutional ownership in Soleno Therapeutics edged up to 127.7% in September 2025, compared to 111.9% in June 2025.
• Quarterly data indicates a 24.47% shift in institutional share volume, and the annual owner count reflects an increase of 66.43%.
• During the quarter, 168 institutions bought more Soleno Therapeutics shares, 57 sold shares, and 13 of the 238 total investors held their position steady.
• This class of investors increased its holdings in Soleno Therapeutics to 67.86Mn shares for the 13F-cycle ending September 2025, up by 13.34Mn shares quarter on quarter, and up 20.35Mn shares year over year.
• With 8.00Mn shares, FMR LLC commands the largest institutional position in Soleno Therapeutics as of September 30, 2025, equating to 15.05% of the company.
• Among the most significant buyers of Soleno Therapeutics during September 2025 were FMR LLC (4.66Mn), WELLINGTON MANAGEMENT GROUP LLP (1.69Mn), BRAIDWELL LP (1.28Mn), Invesco Ltd. (854.55K), Artia Global Partners LP (849.93K).
• Leading sellers of Soleno Therapeutics stock in September 2025 included ADAGE CAPITAL PARTNERS GP, L.L.C. (2.17Mn), Vivo Capital, LLC (1.68Mn), CITADEL ADVISORS LLC (1.13Mn), WESTFIELD CAPITAL MANAGEMENT CO LP (530.60K), SUSQUEHANNA INTERNATIONAL GROUP, LLP (396.69K).
• The top 10 institutional holders of Soleno Therapeutics for the quarter ending September 2025 included FMR LLC (8.00Mn), JANUS HENDERSON GROUP PLC (6.06Mn), PRICE T ROWE ASSOCIATES INC /MD/ (3.90Mn), BlackRock, Inc. (3.49Mn), VANGUARD GROUP INC (2.81Mn), Avoro Capital Advisors LLC (2.58Mn), WELLINGTON MANAGEMENT GROUP LLP (2.31Mn), Vivo Capital, LLC (2.28Mn), STATE STREET CORP (2.17Mn), Invesco Ltd. (1.50Mn).